Literature DB >> 15471965

Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation.

Cecilia H A Gouveia1, Marcelo A Christoffolete, Clarissa R Zaitune, José Miguel Dora, John W Harney, Ana Luiza Maia, Antonio C Bianco.   

Abstract

Thyroid hormone affects multiple aspects of bone metabolism, but little is known about thyroid hormone deiodination in bone cells except that cultures of skeletal cells and bone organ express types 1 and 2 iodothyronine deiodinases (D1 and D2) mRNAs. In the present study, outer ring deiodination (ORD) activity was detected in bone extracts of multiple sites of the mouse skeleton, bone marrow, and the MC3T3-E1 osteoblastic cell line. In all tissues, ORD was detected using 125I-rT3 or 125I-T4 as substrates and was found to be 6-n-propylthiouracil insensitive, display a Michaelis constant (T4) of approximately 1 nM, increase about 3-fold in hypo- and virtually disappear in thyrotoxicosis. Extracts of calvaria had the lowest ORD activity, whereas tibial and femoral extracts had roughly three times as much. The absence of ORD activity in bone extracts from mice with targeted disruption of the Dio2 gene confirms the principal role of D2 in this tissue. In the MC3T3-E1 osteoblasts, D2 activity increased in a time-dependent manner after plating, and with the content of selenium in the media, reaching a maximum 5-7 d later as cells attained more than 90% confluence. In these cells D2 half-life is about 30-40 min, which is further accelerated by exposure to substrate and stabilized by the proteasome inhibitor, MG132. Treatment with vitamin D [1,25(OH)2VD]-induced D2 activity by 2- to 3-fold as early as 24 h, regardless of the level of cell confluence, but estradiol, PTH, forskolin, leptin, TNFalpha, TGFbeta, and dexamethasone did not affect D2. Given the role of D2 in other cell types and processes, it is likely that bone ORD not only plays a role in bone development and adult bone T3 homeostasis but also contributes to extrathyroidal T3 production and maintenance of serum T3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471965     DOI: 10.1210/en.2004-1043

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts.

Authors:  J H Duncan Bassett; Alan Boyde; Peter G T Howell; Richard H Bassett; Thomas M Galliford; Marta Archanco; Holly Evans; Michelle A Lawson; Peter Croucher; Donald L St Germain; Valerie Anne Galton; Graham R Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 2.  Role and Mechanisms of Actions of Thyroid Hormone on the Skeletal Development.

Authors:  Ha-Young Kim; Subburaman Mohan
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 3.  Type 2 deiodinase at the crossroads of thyroid hormone action.

Authors:  Rafael Arrojo E Drigo; Antonio C Bianco
Journal:  Int J Biochem Cell Biol       Date:  2011-06-12       Impact factor: 5.085

Review 4.  Minireview: cracking the metabolic code for thyroid hormone signaling.

Authors:  Antonio C Bianco
Journal:  Endocrinology       Date:  2011-06-28       Impact factor: 4.736

Review 5.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

6.  Thyroid hormone deiodinases D1, D2, and D3 are expressed in human endothelial dermal microvascular line: effects of thyroid hormones.

Authors:  Laura Sabatino; Valter Lubrano; Silvana Balzan; Claudia Kusmic; Serena Del Turco; Giorgio Iervasi
Journal:  Mol Cell Biochem       Date:  2014-10-11       Impact factor: 3.396

7.  Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine.

Authors:  Francesco S Celi; Marina Zemskova; Joyce D Linderman; Sheila Smith; Bart Drinkard; Vandana Sachdev; Monica C Skarulis; Merel Kozlosky; Gyorgy Csako; Rene Costello; Frank Pucino
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

8.  Deiodinase-mediated thyroid hormone inactivation minimizes thyroid hormone signaling in the early development of fetal skeleton.

Authors:  Luciane P Capelo; Eduardo H Beber; Stephen A Huang; Telma M T Zorn; Antonio C Bianco; Cecília H A Gouveia
Journal:  Bone       Date:  2008-07-17       Impact factor: 4.398

9.  Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes.

Authors:  Renata Grozovsky; Scott Ribich; Matthew L Rosene; Michelle A Mulcahey; Stephen A Huang; Mary Elizabeth Patti; Antonio C Bianco; Brian W Kim
Journal:  Endocrinology       Date:  2008-11-26       Impact factor: 4.736

10.  Iodothyronine deiodinase enzyme activities in bone.

Authors:  Allan J Williams; Helen Robson; Monique H A Kester; Johannes P T M van Leeuwen; Stephen M Shalet; Theo J Visser; Graham R Williams
Journal:  Bone       Date:  2008-04-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.